多囊卵巢综合征合并肥胖的无排卵女性恢复排卵与11β-羟基雄烯二酮浓度降低相关
本研究基于一项随机对照试验的数据,纳入95例多囊卵巢综合征合并肥胖且无排卵的女性,接受6个月生活方式干预。恢复排卵组(34例)与持续无排卵组(61例)相比,11β-羟基雄烯二酮变化存在显著差异(交互作用P=0.03),基线AMH较低。作者认为雄激素浓度降低与排卵恢复相关。
要点
- 生活方式干预后恢复排卵与11β-羟基雄烯二酮浓度变化显著相关(交互作用P=0.03)。
- 恢复排卵组基线AMH中位数4.7 ng/ml,低于持续无排卵组的7.2 ng/ml。
- SHBG(交互作用P=0.07)和DHEA-S(交互作用P=0.06)变化呈相似趋势。
核心结论
- 多囊卵巢综合征合并肥胖女性生活方式干预后恢复排卵与血清11β-羟基雄烯二酮浓度变化相关。
- 作者认为若结果在其他研究中得到证实,可在生活方式干预期间监测雄激素浓度以个体化建议恢复排卵时机。
研究设计与样本
- 基于一项随机对照试验(LIFEstyle RCT,荷兰试验注册号NTR 1530)的数据和样本。
- 共577例肥胖女性(BMI>29 kg/m2)于2009年至2012年间随机分组。
- 本分析纳入原试验干预组中多囊卵巢综合征合并肥胖的无排卵女性95例。
- 恢复排卵定义为:自然妊娠;或分配至期待治疗;或生活方式干预后采用自然周期宫腔内人工授精作为治疗策略。
- 恢复排卵组34例,持续无排卵组61例,比较干预后3个月和6个月内分泌与代谢参数变化。
主要发现
- 基线平均年龄恢复排卵组27.5±3.6岁 vs 持续无排卵组27.9±4.1岁(P=0.65)。
- 基线平均体重恢复排卵组101.2±9.5 kg vs 持续无排卵组105.0±14.6 kg(P=0.13)。
- 基线AMH中位数(四分位距)恢复排卵组4.7(3.2; 8.3)ng/ml vs 持续无排卵组7.2(5.3; 10.8)ng/ml。
- 基线雄激素浓度两组间无差异。
- 干预期间及之后两组均体重下降;11β-羟基雄烯二酮变化在恢复排卵组与持续无排卵组间有显著差异(交互作用P=0.03)。
临床怎么用
- 作者认为若结果在其他研究中得到证实,可在生活方式干预期间监测雄激素浓度以个体化建议恢复排卵时机。
局限性
- 未使用高分辨率经阴道超声确认生活方式干预结束时的排卵状态。
- 样本量小可能限制结果的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is resumption of ovulation after a 6-month lifestyle intervention in women with PCOS and obesity associated with differential changes in endocrine and metabolic parameters (weight, insulin resistance, anti-Müllerian hormone (AMH), and androgens) compared to women with PCOS who remained anovulatory? SUMMARY ANSWER: Resumption of ovulation after a 6-month lifestyle intervention in women with PCOS and obesity is associated with changes in serum 11β-hydroxyandrostenedione (11OHA4) concentrations. WHAT IS KNOWN ALREADY: Lifestyle interventions have been shown to reduce clinical and biochemical hyperandrogenism in women with PCOS. Weight loss of 5-10% may reverse anovulatory status, thereby increasing natural conception rates. However, the mechanisms underlying why some women with PCOS remain anovulatory and others resume ovulation after weight loss are unclear. Reproductive characteristics at baseline and a greater degree of change in endocrine and metabolic features with lifestyle intervention may be crucial for ovulatory response. STUDY DESIGN, SIZE, DURATION: We used data and samples originating from an earlier randomized controlled trial (RCT), which examined the efficacy of a 6-month lifestyle intervention prior to infertility treatment compared to prompt infertility treatment on live birth rate in women with obesity. A total of 577 women with obesity (BMI > 29 kg/m2) were randomized between 2009 and 2012. Anovulatory women with PCOS who were allocated to the intervention arm of the original RCT (n = 95) were included in the current analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: We defined women as having resumed ovulation (RO+) based on the following criteria: spontaneous pregnancy; or assignment to expectant management; or IUI in natural cycles as the treatment strategy after lifestyle intervention. Steroid hormones were measured using liquid chromatography tandem mass spectrometry. Generalized estimating equations with adjustment for baseline measures and interaction between group and time was used to examine differences in changes of endocrine and metabolic parameters between RO+ (n = 34) and persistently anovulatory women (RO-, n = 61) at 3 and 6 months after intervention. MAIN RESULTS AND THE ROLE OF CHANCE: At baseline, the mean ± SD age was 27.5 ± 3.6 years in the RO+ group and 27.9 ± 4.1 years in the RO- group (P = 0.65), and the mean ± SD weights were 101.2 ± 9.5 kg and 105.0 ± 14.6 kg, respectively (P = 0.13). Baseline AMH concentrations showed significant differences between RO+ and RO- women (median and interquartile range [IQR] 4.7 [3.2; 8.3] versus 7.2 [5.3; 10.8] ng/ml, respectively). Baseline androgen concentrations did not differ between the two groups. During and after lifestyle intervention, both groups showed weight loss; changes in 11OHA4 were significantly different between the RO+ and RO groups (P-value for interaction = 0.03). There was a similar trend for SHBG (interaction P-value = 0.07), and DHEA-S (interaction P-value = 0.06), with the most pronounced differences observed in the first 3 months. Other parameters, such as AMH and FAI, decreased over time but with no difference between the groups. LIMITATIONS, REASONS FOR CAUTION: No high-resolution transvaginal ultrasonography was used to confirm ovulatory status at the end of the lifestyle program. The small sample size may limit the robustness of the results. WIDER IMPLICATIONS OF THE FINDINGS: Reduction of androgen concentrations during and after lifestyle intervention is associated with recovery of ovulatory cycles. If our results are confirmed in other studies, androgen concentrations could be monitored during lifestyle intervention to provide individualized recommendations on the timing of resumption of ovulation in anovulatory women with PCOS and obesity. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The Department of Obstetrics and Gynecology of the UMCG received an unrestricted educational grant from Ferring Pharmaceuticals BV, The Netherlands. A.H. reports consultancy for the development and implementation of a lifestyle App MyFertiCoach developed by Ferring Pharmaceutical Company. All other authors have no conflicts to declare. TRIAL REGISTRATION NUMBER: The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530).
引用
- Wang Z, Van Faassen M, Groen H, et al. Resumption of ovulation in anovulatory women with PCOS and obesity is associated with reduction of 11β-hydroxyandrostenedione concentrations. Hum Reprod. 2024. PMID: 38503490. doi:10.1093/humrep/deae058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。